TY - JOUR AU - Wilson, W. R. AU - Hay, M. P. PY - 2011 DA - 2011// TI - Targeting hypoxia in cancer therapy JO - Nat Rev Canc VL - 11 UR - https://doi.org/10.1038/nrc3064 DO - 10.1038/nrc3064 ID - Wilson2011 ER - TY - JOUR AU - Toustrup, K. AU - Sorensen, B. S. AU - Nordsmark, M. AU - Busk, M. AU - Wiuf, C. AU - Alsner, J. AU - Overgaard, J. PY - 2011 DA - 2011// TI - Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer JO - Canc Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-1182 DO - 10.1158/0008-5472.CAN-11-1182 ID - Toustrup2011 ER - TY - JOUR AU - Guise, C. P. AU - Abbattista, M. R. AU - Singleton, R. S. AU - Holford, S. D. AU - Connolly, J. AU - Dachs, G. U. AU - Fox, S. B. AU - Pollock, R. AU - Harvey, J. AU - Guilford, P. PY - 2010 DA - 2010// TI - The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3 JO - Canc Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3237 DO - 10.1158/0008-5472.CAN-09-3237 ID - Guise2010 ER - TY - JOUR AU - Singleton, R. S. AU - Guise, C. P. AU - Ferry, D. M. AU - Pullen, S. M. AU - Dorie, M. J. AU - Brown, J. M. AU - Patterson, A. V. AU - Wilson, W. R. PY - 2009 DA - 2009// TI - DNA cross-links in human tumor cells exposed to the prodrug PR-104A: Relationships to hypoxia, bioreductive metabolism and cytotoxicity JO - Canc Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-4023 DO - 10.1158/0008-5472.CAN-08-4023 ID - Singleton2009 ER - TY - JOUR AU - Patterson, A. V. AU - Ferry, D. M. AU - Edmunds, S. J. AU - Gu, Y. AU - Singleton, R. S. AU - Patel, K. AU - Pullen, S. M. AU - Hicks, K. O. AU - Syddall, S. P. AU - Atwell, G. J. PY - 2007 DA - 2007// TI - Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104 JO - Clin Canc Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0478 DO - 10.1158/1078-0432.CCR-07-0478 ID - Patterson2007 ER - TY - JOUR AU - Guise, C. P. AU - Abbattista, M. R. AU - Tipparaju, S. R. AU - Lambie, N. K. AU - Su, J. C. AU - Li, D. AU - Wilson, W. R. AU - Dachs, G. U. AU - Patterson, A. V. PY - 2012 DA - 2012// TI - Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia JO - Mol Pharmacol VL - 81 UR - https://doi.org/10.1124/mol.111.073759 DO - 10.1124/mol.111.073759 ID - Guise2012 ER - TY - JOUR AU - Jameson, M. B. AU - Rischin, D. AU - Pegram, M. AU - Gutheil, J. AU - Patterson, A. V. AU - Denny, W. A. AU - Wilson, W. R. PY - 2010 DA - 2010// TI - A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors JO - Canc Chemother Pharmacol VL - 65 UR - https://doi.org/10.1007/s00280-009-1188-1 DO - 10.1007/s00280-009-1188-1 ID - Jameson2010 ER - TY - JOUR AU - McKeage, M. J. AU - Gu, Y. AU - Wilson, W. R. AU - Hill, A. AU - Amies, K. AU - Melink, T. J. AU - Jameson, M. B. PY - 2011 DA - 2011// TI - A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients JO - BMC Cancer VL - 11 UR - https://doi.org/10.1186/1471-2407-11-432 DO - 10.1186/1471-2407-11-432 ID - McKeage2011 ER - TY - JOUR AU - Noble, S. AU - Goa, K. L. PY - 1997 DA - 1997// TI - Gemcitabine - a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer JO - Drugs VL - 54 UR - https://doi.org/10.2165/00003495-199754030-00009 DO - 10.2165/00003495-199754030-00009 ID - Noble1997 ER - TY - BOOK AU - Sanofi-Aventis, U. S. PY - 2011 DA - 2011// TI - Taxotere (docetaxel) full prescribing information PB - Bridgewater NJ CY - Bridgewater NJ ID - Sanofi-Aventis2011 ER - TY - JOUR AU - Jang, S. H. AU - Wientjes, M. G. AU - Au, J. L. S. PY - 2001 DA - 2001// TI - Determinants of paclitaxel uptake, accumulation and retention in solid tumors JO - Invest New Drugs VL - 19 UR - https://doi.org/10.1023/A:1010662413174 DO - 10.1023/A:1010662413174 ID - Jang2001 ER - TY - JOUR AU - Huxham, L. A. AU - Kyle, A. H. AU - Baker, J. H. E. AU - Nykilchuk, L. K. AU - Minchinton, A. I. PY - 2004 DA - 2004// TI - Microregional effects of gemcitabine in HCT-116 xenografts JO - Canc Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-0986 DO - 10.1158/0008-5472.CAN-04-0986 ID - Huxham2004 ER - TY - JOUR AU - Chapman, J. D. AU - Engelhardt, E. L. AU - Stobbe, C. C. AU - Schneider, R. F. AU - Gerald, G. E. PY - 1998 DA - 1998// TI - Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays JO - Radiother Oncol VL - 46 UR - https://doi.org/10.1016/S0167-8140(97)00186-2 DO - 10.1016/S0167-8140(97)00186-2 ID - Chapman1998 ER - TY - JOUR AU - Therasse, P. AU - Arbuck, S. G. AU - Eisenhauer, E. A. AU - Wanders, J. AU - Kaplan, R. S. AU - Rubinstein, L. AU - Verweij, J. AU - Van Glabbeke, M. AU - van Oosterom, A. T. AU - Christian, M. C. PY - 2000 DA - 2000// TI - New guidelines to evaluate the response to treatment in solid Tumors JO - J Natl Canc Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.3.205 DO - 10.1093/jnci/92.3.205 ID - Therasse2000 ER - TY - JOUR AU - Gu, Y. AU - Wilson, W. R. PY - 2009 DA - 2009// TI - Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: application to a pharmacokinetic study JO - J Chromatogr B Analyt Technol Biomed Life Sci VL - 877 UR - https://doi.org/10.1016/j.jchromb.2009.08.009 DO - 10.1016/j.jchromb.2009.08.009 ID - Gu2009 ER - TY - JOUR AU - Atwell, G. J. AU - Denny, W. A. PY - 2007 DA - 2007// TI - Synthesis of H-3- and H-2(4)-labelled versions of the hypoxia-activated pre-prodrug 2-((2-bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)carbonyl) anilino)ethyl methanesulfonate (PR-104) JO - J Label Compd Radiopharm VL - 50 UR - https://doi.org/10.1002/jlcr.1147 DO - 10.1002/jlcr.1147 ID - Atwell2007 ER - TY - JOUR AU - Gu, Y. AU - Atwell, G. J. AU - Wilson, W. R. PY - 2010 DA - 2010// TI - Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans JO - Drug Metab Dispos VL - 38 UR - https://doi.org/10.1124/dmd.109.030973 DO - 10.1124/dmd.109.030973 ID - Gu2010 ER - TY - JOUR AU - Gu, Y. AU - Tingle, M. D. AU - Wilson, W. R. PY - 2011 DA - 2011// TI - Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-Glucuronosyltransferases, and implications for therapy JO - J Pharmacol Exp Ther VL - 337 UR - https://doi.org/10.1124/jpet.111.180703 DO - 10.1124/jpet.111.180703 ID - Gu2011 ER - TY - JOUR AU - Petrylak, D. P. AU - Macarthur, R. B. AU - O'Connor, J. AU - Shelton, G. AU - Judge, T. AU - Balog, J. AU - Pfaff, C. AU - Bagiella, E. AU - Heitjan, D. AU - Fine, R. PY - 1999 DA - 1999// TI - Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer JO - J Clin Oncol VL - 17 ID - Petrylak1999 ER - TY - JOUR AU - Baker, S. D. AU - Zhao, M. AU - Lee, C. K. K. AU - Verweij, J. AU - Zabelina, Y. AU - Brahmer, J. R. AU - Wolff, A. C. AU - Sparreboom, A. AU - Carducci, M. A. PY - 2004 DA - 2004// TI - Comparative pharmacokinetics of weekly and every-three-weeks docetaxel JO - Clin Canc Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-0842-03 DO - 10.1158/1078-0432.CCR-0842-03 ID - Baker2004 ER - TY - JOUR AU - Extra, J. M. AU - Rousseau, F. AU - Bruno, R. AU - Clavel, M. AU - Lebail, N. AU - Marty, M. PY - 1993 DA - 1993// TI - Phase-I and pharmacokinetic study of Taxotere(RP-56976, NSC-628503) given as a short intravenous-infusion JO - Canc Res VL - 53 ID - Extra1993 ER - TY - JOUR AU - Abbruzzese, J. L. AU - Grunewald, R. AU - Weeks, E. A. AU - Gravel, D. AU - Adams, T. AU - Nowak, B. AU - Mineishi, S. AU - Tarassoff, P. AU - Satterlee, W. AU - Raber, M. N. PY - 1991 DA - 1991// TI - A phase-I clinical, plasma and cellular pharmacology study of gemcitabine JO - J Clin Oncol VL - 9 ID - Abbruzzese1991 ER - TY - JOUR AU - Fogli, S. AU - Danesi, R. AU - Braud, F. D. AU - Pas, T. D. AU - Curigliano, G. AU - Giovannetti, E. AU - Del Tacca, M. PY - 2001 DA - 2001// TI - Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer JO - Ann Oncol VL - 12 UR - https://doi.org/10.1023/A:1013133415945 DO - 10.1023/A:1013133415945 ID - Fogli2001 ER - TY - JOUR AU - Hall, A. G. AU - Tilby, M. J. PY - 1992 DA - 1992// TI - Mechanisms of action of, and modes of resistance to, alkylating-agents used in the treatment of hematological malignancies JO - Blood Rev VL - 6 UR - https://doi.org/10.1016/0268-960X(92)90028-O DO - 10.1016/0268-960X(92)90028-O ID - Hall1992 ER - TY - JOUR AU - Patel, K. AU - Choy, S. S. F. AU - Hicks, K. O. AU - Melink, T. J. AU - Holford, N. H. G. AU - Wilson, W. R. PY - 2011 DA - 2011// TI - A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity JO - Canc Chemother Pharmacol VL - 67 UR - https://doi.org/10.1007/s00280-010-1412-z DO - 10.1007/s00280-010-1412-z ID - Patel2011 ER - TY - JOUR AU - Rischin, D. AU - Peters, L. AU - Hicks, R. AU - Hughes, P. AU - Fisher, R. AU - Hart, R. AU - Sexton, M. AU - D'Costa, I. AU - von Roemeling, R. PY - 2001 DA - 2001// TI - Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer JO - J Clin Oncol VL - 19 ID - Rischin2001 ER - TY - JOUR AU - Borad, M. AU - Mita, A. AU - Infante, J. AU - Chiorean, E. G. AU - Vlahovic, G. AU - Armstrong, A. AU - Traynor, A. M. AU - Schelman, W. AU - Langmuir, V. AU - Eng, C. PY - 2010 DA - 2010// TI - Complete phase Ib study of TH-302 in combination with gemcitabine (G), docetaxel (D) or pemetrexed (P) JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdq203 DO - 10.1093/annonc/mdq203 ID - Borad2010 ER - TY - JOUR AU - Ryan, D. AU - Reddy, S. AU - Bahary, N. AU - Uronis, H. AU - Sigal, D. S. AU - Cohn, A. AU - Schelman, W. R. AU - Chiorean, E. G. AU - Rosen, P. J. AU - Ulrich, B. PY - 2012 DA - 2012// TI - Phase II study of gemcitabine + TH-302 vs gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer JO - Ann Oncol VL - 23 ID - Ryan2012 ER - TY - JOUR AU - Weiss, G. J. AU - Infante, J. R. AU - Chiorean, E. G. AU - Borad, M. J. AU - Bendell, J. C. AU - Molina, J. R. AU - Tibes, R. AU - Ramanathan, R. K. AU - Lewandowski, K. AU - Jones, S. F. PY - 2011 DA - 2011// TI - Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies JO - Clin Canc Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-3425 DO - 10.1158/1078-0432.CCR-10-3425 ID - Weiss2011 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/496/prepub UR - http://www.biomedcentral.com/1471-2407/12/496/prepub ID - ref30 ER -